Clinical Excellence

Crescent Theranostics sits at the intersection of precision, compassion, and innovation.

Our Mission: Delivering Life-Changing Outcomes Through Precision Theranostics

At Crescent Theranostics, clinical excellence is more than a philosophy — it’s the foundation of everything we do. Our multidisciplinary team integrates radiology, nuclear medicine, oncology, and advanced imaging to deliver personalized, data-driven care using the most advanced radiopharmaceutical therapies available today.

We measure success not just by industry benchmarks — but by lives improved, hope restored, and outcomes redefined.

Outcomes That Matter

Proven Results with Pluvicto (Lu-177 PSMA-617)

  • 80% of eligible patients demonstrate measurable disease control after Pluvicto therapy*
  • High targeting accuracy with PSMA PET-based selection and dosimetry optimization
  • Reduced pain and narcotic use reported by mCRPC patients within 2–3 cycles

Exceptional Efficacy with Lutathera (Lu-177 DOTATATE)

  • Median Progression-Free Survival (PFS) of >29 months in GEP-NET patients
  • 60% reduction in tumor burden seen in post-treatment Ga-68 DOTATATE PET/CT imaging

Quality You Can Trust

Our internal and external quality benchmarks meet or exceed national standards for safety, accuracy, and effectiveness in radiopharmaceutical therapy.

Key Quality Highlights:

  • 100% compliance with NRC, CMS, HIPAA, and USP standards
  • Board-certified nuclear medicine and radiology specialists overseeing all therapy decisions
  • Quarterly outcomes audits and tumor board review

Safety and Accountability

  • Zero major adverse events across hundreds of Pluvicto and Lutathera administrations
  • Active monitoring of labs, renal function, marrow reserve, and radiation exposure
  • Institutional safety drills, shielding protocols, and radiation monitoring logs
  • 99% of patients complete therapy without hospitalization or interruption

Why Clinical Excellence Matters

When patients are fighting aggressive disease — precision, safety, and trust are non-negotiable. Our commitment to clinical excellence means every patient at Crescent Theranostics receives:

  • Evidence-based care tailored to their biology
  • Real-time decision-making by subspecialists
  • Access to emerging science through trials and innovation
  • We are proud to deliver world-class outcomes with compassion and clarity.

Our Commitment to Quality & Safety

  • ????️ Flawless Safety Record: Crescent Theranostics has maintained a zero incident record in radiopharmaceutical handling and therapy delivery since inception.
  • ???? Comprehensive Regulatory Compliance: Fully compliant with NRC, CMS, HIPAA, and state-level radiation safety regulations, with all required licenses and certifications current.
  • ???? National Accreditation & Inspections: Successfully passed all federal and state inspections with no major citations during annual and unannounced audits.
  • ✅ Good Manufacturing & Compounding Practices (GMP/CSP standards): Adherence to USP <825> and <797> standards for radiopharmaceutical preparation, sterility, and administration.
  • ???? Ongoing Quality Assurance (QA): Internal QA protocols ensure daily dose calibration, equipment validation, and patient-specific verification checks before therapy.
  • ???? Emergency Preparedness: Fully trained staff and systems in place for radiation safety drills, with quarterly audits and simulations.
  • ???? Patient-Centered Safety Monitoring: Each patient undergoing Pluvicto or Lutathera therapy is monitored in accordance with best-in-class dosing, renal function, and radiation safety guidelines.

????‍⚕️ Clinical Excellence Audits: Quarterly internal reviews and cross-checks by medical directors ensure evidence-based adherence to clinical pathways and patient outcomes tracking.